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Abstract
As the competing interests for only the previous calendar year were included in the published
article and it is journal policy to list competing interests for the previous five years, a full declaration
of interests for the authors is now published.  
As the competing interests for only the previous calendar year
were included in the published article [1] and it is journal pol-
icy to list competing interests for the previous five years, a full
declaration of interests for the authors is as follows:
During this time, Dr. Corey was a consultant to a company
involved in developing an HSV vaccine (Antigenics). His role
was to advise the company on what potential HSV proteins
they should select for their peptide based vaccine.
Dr. Corey has been the lead investigator of several trials that
used HSV serologies as a critical component of the study. These
trials have used either the University of Washington Western
blot or the Focus assay followed by the University of Washing-
ton Western blot. All grant funds associated with these trials
were paid to the University of Washington to support person-
nel and supplies associated with the work. Dr. Corey received
no salary support from these funds.
Dr. Corey is associated with a company which sponsors an
informational website that is available to anyone with internet
access without charge [2]. The website was created as a public
service to health care providers and the lay public. Dr. Corey
writes content appearing on the website. In the years 2002 to
2004, Focus Technologies, as well as several private individuals
and companies involved in HSV therapy provided funding to
support development of new content as well as periodically
revise and maintain the website. Dr. Corey received compensa-
tion for writing and revising content on the website which pro-
vides information on the epidemiology, clinical
manifestations, therapy and diagnosis of HSV infection. His
editorial responsibilities did not involve the area of HSV serol-
ogy.
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